Airobes
Biotechnology platform converting atmospheric CO₂ into valuable proteins and lipids using a two-organism system.
Website: https://airobes.com/
Cover Block
Public sources
| Field | Detail |
|---|---|
| Name | Airobes |
| Tagline | Biotechnology platform converting atmospheric CO₂ into valuable proteins and lipids using a two-organism system. |
| Headquarters | Phoenix, United States [Phoenix Bioscience Core, November 2025] |
| Founded | 2024 [Phoenix Bioscience Core, November 2025] |
| Stage | Seed |
| Business model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) [Phoenix Bioscience Core, November 2025] |
| Funding label | Pre-seed [Fundz, September 2024] |
| Total disclosed | ~$125,000 [SEC Form D, September 2025] |
Links
Public sources
- Website: https://airobes.com/
Executive Summary
PUBLIC Airobes is a Phoenix biotechnology startup building a carbon-to-value platform that uses algae and bacteria to turn atmospheric or captured CO2 into recombinant proteins and lipids, a concept that merits attention because the company says it has already brought an initial research reagent, Taq DNA Polymerase, to market while keeping the broader platform tied to carbon-economics upside [BIO International Convention, 2026] [StartupSeeker] [Phoenix Bioscience Core, November 2025]. Founded in 2024 by Arizona State University alumni Erik Eshima, Jarrett Eshima, and Dhruva Moudgal, the company appears to be early but unusually specific in its technical wedge: a two-organism system in which algae capture or recycle carbon and bacteria use that feedstock for recombinant-protein production [Phoenix Bioscience Core, November 2025] [BIO International Convention, 2026].
The immediate commercial story is narrower than the platform narrative, which is a positive at this stage. Airobes' first product is a research-use-only Taq DNA Polymerase, and its public BIO profile states that product reached the market in Q4 2025, giving investors a clearer near-term testing ground than a pure long-dated climate biotech claim would provide [BIO International Convention, 2026].
The team is still small, with LinkedIn indicating 1 to 10 employees, but the founders' identities and roles are reasonably well anchored in public sources: Jarrett Eshima is identified as co-founder and CEO, Dhruva Moudgal as co-founder and COO, and Erik Eshima as a related person and executive officer/director in securities filings [LinkedIn, Retrieved 2026] [Venture Café Phoenix, October 2025] [Airobes, Retrieved 2026] [SEC Form D, September 2025]. Public materials also place the company within the Phoenix Bioscience Core ecosystem and note participation in 1871's Climate Tech Innovation Lab, which suggests some institutional support even if commercial validation remains early [Phoenix Bioscience Core, November 2025] [1871].
Capital formation remains modest by venture biotech standards. Public filings and funding databases show $125,000 disclosed across two pre-seed raises, including $75,000 in September 2024 and $50,000 in September 2025, with no confirmed lead investor named in the sourced material, and the stated business model is B2B [Fundz, September 2024] [SEC Form D, September 2025].
Over the next 12 to 18 months, the key question is whether Airobes can convert an interesting biological-production thesis into repeatable commercial proof: additional reagent sales, evidence that the carbon-to-protein process scales beyond gram-level milestones, and sharper disclosure on customers or partners would all matter materially more than broad platform ambition at this point [1871] [BIO International Convention, 2026]. The setup is early, technically differentiated in public description, and still short on third-party operating evidence, which is typical for a company at this funding level but leaves diligence centered on reproducibility, unit economics, and market pull rather than concept alone [SEC Form D, September 2025] [Phoenix Bioscience Core, November 2025].
Lightly corroborated -- Relies on a mix of independent public sources, including SEC filings, Phoenix Bioscience Core, Venture Café Phoenix, and BIO International Convention, with some product-detail support coming from company and event materials.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Pre-seed (total disclosed ~$125,000) |
How the Company Got Here
PUBLIC
Airobes is a Phoenix-based biotechnology startup formed in 2024 and organized as Airobes LLC, according to company materials and securities filings [Airobes] [SEC Form D, September 2025]. The public record is still thin, but the through-line is clear enough: the company was started by three Arizona State University alumni, Erik Eshima, Jarrett Eshima, and Dhruva Moudgal, and is developing a biological carbon-conversion platform from a laboratory base inside the Phoenix Bioscience Core [Phoenix Bioscience Core, November 2025] [Airobes] [SEC Form D, September 2025].
The early milestones are modest in scale but reasonably well dated. Airobes appeared in public funding databases with a $75,000 pre-seed financing in September 2024 [Fundz, September 2024]. By November 2025, Phoenix Bioscience Core described the company as advancing biological carbon capture technology from its Phoenix location and collaborating with Arizona State University-linked infrastructure [Phoenix Bioscience Core, November 2025]. A September 2025 Form D filing shows an additional $50,000 in disclosed private capital, bringing the publicly visible total to $125,000 across the two pre-seed financings [SEC Form D, September 2025] [Fundz, September 2024].
The operational footprint also looks local and early-stage, which is consistent with the financing profile. The company website presents Airobes as a carbon-recycling biotech business, while third-party and event materials place the team in downtown Phoenix and tie the founding story to the ASU ecosystem rather than to a prior spun-out venture or institutional lab commercialization process [Airobes] [Phoenix Bioscience Core, November 2025]. For investors, that does not settle the question of technical defensibility, but it does establish the basic company identity, location, founding cohort, and first visible funding path.
Lightly corroborated -- Core identity, founding year, Phoenix location, and legal entity are supported by company materials and SEC filings, but chronology beyond the disclosed financings relies partly on a single local institutional source.
Product and Technology
MIXED Airobes is building a carbon-to-value biomanufacturing platform around a two-organism process, and the interesting part is not the language of carbon utilization on its own but the stated production logic. Public descriptions from the company and event materials say algae first capture or recycle atmospheric or captured CO₂, after which bacteria use that carbon feedstock to produce recombinant proteins [BIO International Convention, 2026] [Airobes] [StartupSeeker]. The public record is consistent that the company is using microorganisms as the operating layer and that its framing emphasizes mass balance rather than a pure genetic-engineering story, although that latter characterization appears in third-party profile material rather than a primary technical disclosure [StartupSeeker].
The initial commercial wedge appears narrower than the platform language suggests, which is often the right way to read an early biotech company. Airobes' first product is a research-use-only Taq DNA Polymerase, and its BIO International Convention profile states that this product reached the market in Q4 2025 [BIO International Convention, 2026]. Broader claims, including the potential to produce thousands of recombinant proteins across diagnostics, therapeutics, and research reagents, are present in public summaries but remain forward-looking and lightly corroborated relative to the near-term evidence of a single RUO reagent launch [BIO International Convention, 2026].
The technical validation disclosed publicly is still early. Phoenix Bioscience Core reported that Airobes had achieved gram-scale carbon removal, which supports the view that the company has moved beyond a purely conceptual system, but that is still a long distance from showing repeatable industrial bioprocess economics or scaled protein output [Phoenix Bioscience Core, November 2025]. Public materials also describe a protein-and-lipid manufacturing model intended to improve feedstock economics, yet the available sources do not provide yield data, throughput, unit-cost benchmarks, or third-party performance testing, so the present evidence is better read as proof of direction than proof of scale [Airobes] [BIO International Convention, 2026].
Company-stated, unverified -- This section relies materially on company and event-profile descriptions, with limited independent technical corroboration.
Where the Demand Sits
PUBLIC
The market matters because Airobes is trying to sit at the intersection of two active spending pools, carbon management and life-science reagents, at a moment when buyers in both categories are looking for lower-cost inputs and more resilient supply chains [BIO International Convention, 2026] [Phoenix Bioscience Core, November 2025].
Public evidence does not support a direct TAM, SAM, or SOM for Airobes itself, and there is no cited third-party market report in the source set that sizes carbon-to-protein or carbon-to-value biomanufacturing as a standalone category. What is observable is the wedge: Airobes says its first product is research-use-only Taq DNA Polymerase, and its BIO profile places that product in market as of Q4 2025 [BIO International Convention, 2026]. That matters because it gives the company an entry point into the broader research reagents economy rather than requiring immediate adoption in therapeutics, fuels, or compliance carbon markets, each of which carries a longer qualification cycle [BIO International Convention, 2026].
The demand logic rests on two public tailwinds. First, the company is framing carbon not as a waste stream to be stored, but as a feedstock for proteins and lipids, which aligns with a wider industrial push to convert emissions into usable inputs rather than treat carbon management as a pure cost center [Phoenix Bioscience Core, November 2025] [StartupSeeker]. Second, the product pathway starts with a standard laboratory reagent instead of a regulated biologic, which should shorten the path to early commercial validation if quality and unit economics hold [BIO International Convention, 2026]. The sources do not establish current customer demand, signed contracts, or repeat purchasing, so any view of market pull should remain provisional [BIO International Convention, 2026].
Adjacent markets are easier to identify than the core category itself. On one side sits carbon capture and carbon removal, which Airobes and 1871-associated materials describe as part of the company narrative, including a claimed gram-scale carbon removal milestone [1871] [Phoenix Bioscience Core, November 2025]. On the other sits industrial and research biomanufacturing, where recombinant proteins, diagnostics inputs, and laboratory enzymes are familiar procurement categories with existing budgets and incumbent suppliers [BIO International Convention, 2026]. Airobes' own description of the platform extends beyond Taq polymerase toward diagnostics, therapeutics, and research reagents, but that should be read as capability ambition rather than demonstrated market reach [BIO International Convention, 2026].
The regulatory and macro backdrop is favorable in direction, but still indirect at this stage. Carbon accounting pressure, industrial decarbonization programs, and university-linked climate tech ecosystems appear to be helping the company access early commercialization infrastructure, including Phoenix Bioscience Core and the Climate Tech Innovation Lab at 1871 [Phoenix Bioscience Core, November 2025] [1871]. At the same time, once a platform moves from research-use-only reagents toward therapeutic or food-linked outputs, the compliance burden would rise materially, and the current public record does not show that transition underway [BIO International Convention, 2026]. That leaves the near-term market case centered on whether Airobes can prove that carbon-derived production is cost-competitive and reliable in narrow reagent use cases before expanding into heavier-regulated adjacencies [BIO International Convention, 2026] [Phoenix Bioscience Core, November 2025].
| Cited market lens | Relevance to Airobes | Evidence |
|---|---|---|
| Research-use-only reagents | Initial commercial wedge through Taq DNA Polymerase | Taq DNA Polymerase reached market in Q4 2025 [BIO International Convention, 2026] |
| Carbon capture and removal | Potential secondary economics and climate positioning | Company-associated sources describe secondary revenue potential and gram-scale carbon removal [1871] [Phoenix Bioscience Core, November 2025] |
| Recombinant protein production | Longer-term platform expansion path | BIO profile describes applications in diagnostics, therapeutics, and research reagents [BIO International Convention, 2026] |
| Biofuel feedstock | Possible downstream value from lipid production | Company-associated description says protein and lipid manufacturing could support renewable biofuel feedstock economics [Airobes] |
The table underscores a simple point: the closest observable market is laboratory reagents, while the larger climate and industrial biology opportunities remain adjacent and mostly unproven in the public record. For investors, that narrows early diligence to product quality, production cost, and repeatability rather than headline carbon-market size claims.
Lightly corroborated -- Section relies primarily on BIO International Convention and Phoenix Bioscience Core, with some adjacent claims from company-associated materials and 1871-linked reporting.
Competitive Landscape
MIXED Airobes is positioning itself less against a single named startup rival than against established protein-input supply chains and conventional carbon-utilization approaches, which makes the competitive question one of substitute economics as much as direct category rivalry [BIO International Convention, 2026] [Phoenix Bioscience Core, November 2025].
The public record supports three comparison sets. First are incumbent reagent suppliers in life-science tools, where Airobes' initial wedge is research-use-only Taq DNA Polymerase, a mature product class sold by large catalog vendors with existing laboratory distribution, quality systems, and purchasing relationships [BIO International Convention, 2026]. Second are carbon capture and carbon utilization programs, where the company's pitch is that captured or atmospheric CO2 can become feedstock for proteins and lipids rather than a waste stream to store or a commodity input to sell at low margin [Phoenix Bioscience Core, November 2025]. Third are adjacent biomanufacturing platforms, including firms built around fermentation, synthetic biology, or algae-based production, although the supplied sources do not name specific private-company peers, so the comparison has to stay at the level of model rather than head-to-head operator benchmarking [StartupSeeker] [BIO International Convention, 2026].
That framing matters because Airobes' clearest edge today appears to be technical positioning, not market control. Public materials describe a two-organism system in which algae capture or recycle carbon and bacteria use the resulting carbon feedstock to produce recombinant proteins, with a longer-term claim that combining protein and lipid output could improve overall process economics [BIO International Convention, 2026] [Phoenix Bioscience Core, November 2025]. If that architecture works outside benchtop conditions, it could let the company compete on feedstock logic rather than only on downstream protein pricing.
The problem is that this edge still looks perishable. The company has disclosed $125,000 across two pre-seed financings and a team size in the 1 to 10 range, which is modest relative to the capital, process-development time, and commercial validation usually required for biomanufacturing scale-up [Fundz, September 2024] [SEC Form D, September 2025] [LinkedIn]. Larger incumbents in reagents do not need Airobes' carbon thesis to defend their installed base, and better-capitalized climate or synthetic-biology entrants could pursue similar carbon-to-value concepts if the unit economics begin to look credible [BIO International Convention, 2026].
Airobes is most exposed where channel ownership and proof requirements are highest. In research reagents, established suppliers already own procurement workflows and customer trust around consistency, documentation, and fulfillment, while Airobes has only a recently launched product claim and no named customers in the supplied public record [BIO International Convention, 2026]. In carbon-removal markets, the company has cited gram-scale carbon removal through the 1871 program, but that is still far from the measurement, verification, and scale thresholds that matter for serious offtake or credit buyers [1871].
The most plausible 18-month competitive scenario is bifurcated. Airobes is the winner if laboratory customers accept the Taq product as a credible foothold and the company can use that narrow commercial proof to raise enough capital for process validation beyond benchtop systems [BIO International Convention, 2026] [Fundz, September 2024]. Airobes is also the loser if incumbent reagent vendors keep pricing and service pressure high while the carbon-to-protein platform remains technically interesting but under-capitalized, because in that case the company would be competing against established distribution before it has demonstrated manufacturing scale or a proprietary commercial channel [SEC Form D, September 2025] [Phoenix Bioscience Core, November 2025].
Single unverified source -- Core positioning is supported by BIO International Convention and Phoenix Bioscience Core, but competitor-specific benchmarking is limited because no named direct competitors are provided in the sourced facts and several platform claims remain company or event-profile based.
Opportunity
PUBLIC
The size of the prize here is not a single lab reagent line, but a carbon-fed biomanufacturing platform that could move from one research-use enzyme into a broader class of proteins and lipids if the process proves economical outside the lab [BIO International Convention, 2026] [Phoenix Bioscience Core, November 2025].
The headline opportunity is straightforward: Airobes could become a specialized carbon-to-protein production platform for research and industrial biology inputs, starting with Taq DNA Polymerase and extending into additional recombinant proteins if its two-organism system scales with acceptable yield and cost [BIO International Convention, 2026] [Airobes, Unknown]. That outcome is still early, but it is not purely aspirational. Public materials indicate the company already has an initial commercial product in market, Taq DNA Polymerase, and describes a process architecture in which algae capture or recycle carbon and bacteria use that carbon feedstock to produce recombinant proteins [BIO International Convention, 2026]. The practical significance is that Airobes is not asking the market to underwrite a platform before any wedge exists. It is trying to enter through a known reagent category first, then widen the surface area of what the same production logic can make [BIO International Convention, 2026].
Airobes' public record supports a few distinct upside paths, each of which depends on execution rather than category invention.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Research reagent beachhead | The company builds a credible revenue base by selling Taq DNA Polymerase, then adds adjacent research-use recombinant proteins to laboratory and biotech buyers | Commercial adoption of the initial Taq product after its reported Q4 2025 market entry [BIO International Convention, 2026] | Airobes has already identified Taq DNA Polymerase as its first commercial product and says it reached market in Q4 2025, which gives it a narrower and more legible first route than launching directly into regulated therapeutics [BIO International Convention, 2026] |
| Carbon-to-protein platform expansion | The company uses the same carbon-fed production system to supply a broader catalog of recombinant proteins across diagnostics, therapeutics, and research applications | Demonstrated reproducibility of the two-organism system beyond one enzyme class [BIO International Convention, 2026] | The BIO profile states the platform is designed for multiple recombinant-protein applications, and the company frames the system as a general production method rather than a single-product process [BIO International Convention, 2026] [Airobes, Unknown] |
| Dual-value carbon economics | The company pairs product revenue with carbon capture or carbon removal economics, improving the cost structure of biological manufacturing | Verified scale-up from benchtop work toward larger carbon-removal and production runs [Phoenix Bioscience Core, November 2025] [1871] | Company and ecosystem materials describe secondary revenue potential from carbon capture and note a gram-scale carbon-removal milestone, suggesting management is trying to build economics around both molecule output and carbon handling rather than product sales alone [Phoenix Bioscience Core, November 2025] [1871] |
The compounding mechanism, if it appears, would likely come from process reuse rather than a classic software network effect. Airobes' public materials describe one core system, algae capturing or recycling carbon and bacteria converting that feedstock into recombinant proteins, with the possibility of supporting many downstream molecules from the same biological production base [BIO International Convention, 2026]. If that base process improves with each production run, better yields, lower input costs, and faster product development could make each additional protein easier to launch than the first. The earliest sign of that flywheel is structural rather than financial: the company has already moved from platform narrative to an initial marketed reagent, while continuing to describe a broader set of protein applications and lipid co-production logic [BIO International Convention, 2026] [Airobes, Unknown].
The size of the win is hard to anchor precisely because no public market-sizing figure or direct comparable is confirmed in the available source set. Even so, the shape of the upside is visible. If Airobes became a credible supplier of carbon-derived research and industrial biology inputs, rather than a single-product reagent vendor, the company could plausibly resemble a platform biotech tools business more than a narrow climate experiment (scenario, not a forecast) [BIO International Convention, 2026] [Phoenix Bioscience Core, November 2025]. The gating issue is whether the company can show that carbon utilization improves production economics in a repeatable way. If it can, the commercial surface expands from one enzyme to a broader catalog, and from product margin alone to a model that may also capture value from carbon management [BIO International Convention, 2026] [Airobes, Unknown].
Company-stated, unverified -- This section relies materially on company and event-profile claims about product scope, platform potential, and commercialization, with limited independent public corroboration beyond founder identity, location, and disclosed financing.
Sources
Public sources
[Phoenix Bioscience Core, November 2025] Turning Emissions Into Assets: Airobes Advances Biological Carbon Capture Technology | https://phoenixbiosciencecore.com/news/turning-emissions-into-assets-airobes-advances-biological-carbon-capture-technology/11/2025/
[Fundz, September 2024] Airobes $75,000 pre-seed 2024-09-26 | https://app.fundz.net/fundings/airobes-funding-round-124eda
[SEC Form D, September 2025] Form D/A Airobes, LLC | https://www.streetinsider.com/SEC+Filings/Form+DA+Airobes,+LLC/24609325.html
[BIO International Convention, 2026] Airobes LLC - BIO International Convention 2026 | https://convention.bio.org/2026-sessions-and-courses/airobes-llc
[LinkedIn, Retrieved 2026] Benjamin Ambrose - Field Service Engineer at LECO | https://www.linkedin.com/in/benjamin-ambrose-0400b9277/
[Venture Café Phoenix, October 2025] Jarrett Eshima | https://venturecafephoenix.org/speakers/jarrett-eshima/
[Airobes, Retrieved 2026] Airobes - Biologically Recycling Carbon Emissions | https://airobes.com/team
Articles about Airobes
- Airobes’s First Product Is a Research Enzyme Made From Air — The Phoenix-based biotech has raised $125,000 to prove its carbon-to-value platform can scale from gram-scale removal to commercial reagents.